<scp>FERM</scp> domain‐containing protein 6 exerts a tumor‐inhibiting role in thyroid cancer by antagonizing oncogenic <scp>YAP1</scp>

Wang, Wei; Zhao, Chuanqi; Fang, Quan; Zhang, Pengfei; Shao, Yuan; Liu, Lifeng

doi:10.1002/biof.1791

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FRMD6 was previously validated as a key upstream regulator of the Hippo signaling pathway that exerted an anti-tumor effect in several human cancers [37]. A recent study demostrated that FRMD6 had a tumor suppressor role by suppressing the activation of carcinogenic YAP1 in thyroid cancer [38]. While Haldrup et al reported that FRMD6 worked as a tumor suppressor gene in prostate cancer [39], they did not explore the upstream regulatory mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Activation of the HNRNPA2B1/miR-93-5p/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner

Sun¹,

Shen²,

Jia³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

It is becoming increasingly clear that N6-methyladenosine (m6A) plays a key role in post-transcriptional modification of eukaryotic RNAs in cancer. The regulatory mechanism of m6A modifications in prostate cancer is still not completely elucidated. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1), an m6A reader, has been revealed to function as an oncogenic RNA-binding protein. However, its contribution to prostate cancer progression remains poorly understood. Here, we found that HNRNPA2B1 was highly overexpressed and correlated with a poor prognosis in prostate cancer. In vitro and in vivo functional experiments demonstrated that HNRNPA2B1 knockout impaired proliferation and metastasis of prostate cancer. Mechanistic studies indicated that HNRNPA2B1 interacted with primary miRNA-93 and promoted its processing by recruiting DiGeorge syndrome critical region gene 8 (DGCR8), a key subunit of the Microprocessor complex, in an METTL3-dependent mechanism, while HNRNPA2B1 knockout significantly restored miR-93-5p levels. HNRNPA2B1/miR-93-5p downregulated FERM domain-containing protein 6 (FRMD6), a cancer suppressor, and enhanced proliferation and metastasis in prostate cancer. In conclusion, our findings identified a novel oncogenic axis, HNRNPA2B1/miR-93-5p/FRMD6, that stimulates prostate cancer progression via an m6A-dependent manner.

show abstract

Section: Discussionmentioning

confidence: 99%

Activation of the HNRNPA2B1/miR-93-5p/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner

Sun¹,

Shen²,

Jia³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Therefore, it also indirectly indicates that there is a correlation between FLNC and hypoxia. Cell test and tissue test showed that FERM domain containing 6 (FRMD6) had tumor inhibitory effect in prostate cancer [ 29 ] and thyroid cancer [ 30 ]. In contrast, FRMD6 is a wind risk factor that threatens the prognosis of LUAD in our study.…”

Section: Discussionmentioning

confidence: 99%

A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

Yang

Liang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Hypoxia is a typical microenvironmental feature of most solid tumors, affecting a variety of physiological processes. We developed a hypoxia-related prognostic risk score (HPRS) model to reveal tumor microenvironment (TME) and predict prognosis of lung adenocarcinoma (LUAD). Methods. LUAD sample expression data were from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Weighted gene co-expression network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) Cox regression identified hypoxia-related genes (HRGs) to create HPRS. The prognostic value, genetic mutation and TME, and therapeutic response of distinct HPRS groups were analyzed. Univariate and multivariate Cox regression analysis identified independent factors associated with the prognosis of LUAD. A decision tree based on HPRS and clinicopathological variables was established using the classification system based on decision tree algorithm. A nomogram was constructed with important clinical features and HPRS by the RMS package. Results. A HPRS model with five HRGs was developed and verified in two separate cohorts of GEO. HPRS model divided patients with LUAD into two groups. High HPRS was related to high probability of genetic alterations. HPRS could predict the prognosis, TME, and sensitivity to immunotherapy/chemotherapy of LUAD. The decision tree defined four risk subgroups with significant OS differences. Nomogram with integrated HPRS and clinical features had acceptable accuracy in predicting LUAD prognosis. Conclusions. A HPRS model was developed to evaluate prognosis, genetic alterations, TME, and response to immunotherapy, which may provide theoretical reference for the study of molecular mechanism of hypoxia in LUAD.

show abstract

CircRNA VPRBP inhibits tumorigenicity of cervical cancer via miR-93-5p/FRMD6 axis

Shen

Dang²,

Liu

et al. 2022

Reprod. Sci.

View full text Add to dashboard Cite

FERM domain‐containing protein 6 exerts a tumor‐inhibiting role in thyroid cancer by antagonizing oncogenic YAP1

Cited by 5 publications

References 31 publications

Activation of the HNRNPA2B1/miR-93-5p/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner

Activation of the HNRNPA2B1/miR-93-5p/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner

A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

CircRNA VPRBP inhibits tumorigenicity of cervical cancer via miR-93-5p/FRMD6 axis

Contact Info

Product

Resources

About